2222-07-3
基本信息
葫芦素 I
葫芦素I(甄准不供应)
Ibamarin
ELATERIN B
NSC 521777
ELATERICIN B
CUCURBITACIN I
5-tetrahydroxy-
cucurbitacine(i)
CUCURBITACIN I(SH)
CUCURBITACIN I hplc
物理化学性质
熔点 | 148-150°C |
沸点 | 698.3±55.0 °C(Predicted) |
密度 | 1.26±0.1 g/cm3(Predicted) |
储存条件 | -20°C |
溶解度 | ≥22.45 mg/mL in DMSO; insoluble in EtOH; ≥51.2 mg/mL in H2O with ultrasonic |
酸度系数(pKa) | 8.51±0.70(Predicted) |
形态 | 固体 |
颜色 | 白色至灰白色 |
LogP | 2.330 (est) |
安全数据
危险性符号(GHS) | GHS06 |
警示词 | 危险 |
危险性描述 | H301 |
防范说明 | P301+P330+P331+P310 |
危险品标志 | Xi,T+ |
危险类别码 | 25-28 |
安全说明 | 1-22-45-36/37-28 |
危险品运输编号 | UN 2811 6.1/PG 1 |
危险品运输编号 | UN 2811 6.1/PG 1 |
WGK Germany | 3 |
RTECS号 | RC6200000 |
毒性 | LD50 oral in mouse: 5mg/kg |
葫芦素 I价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/11/08 | HY-N1405 | 葫芦素 I Cucurbitacin I | 2222-07-3 | 1mg | 1480元 |
2024/11/08 | HY-N1405 | 葫芦素 I Cucurbitacin I | 2222-07-3 | 5mg | 3780元 |
2024/11/08 | HY-N1405 | 葫芦素 I Cucurbitacin I | 2222-07-3 | 10mM * 1mLin DMSO | 4280元 |
常见问题列表
JAK2
|
STAT3
|
Exposure of the COLO205 cells to Cucurbitacin I significantly decreases cell viability. The anticancer activity of Cucurbitacin I is accomplished by downregulating p-STAT3 and MMP-9 expression. PE-induced cell enlargement and upregulation of ANF and β-MHC are significantly suppressed by pretreatment of the cardiomyocytes with Cucurbitacin I. Notably, Cucurbitacin I also impaires connective tissue growth factor (CTGF) and MAPK signaling, pro-hypertrophic factors, as well as TGF-β/Smad signaling, the important contributing factors to fibrosis. Incubation of the Seax cell line with the Jak/Stat3 inhibitor Cucurbitacin I result in a time- and concentration-dependent decrease of P-Stat3 and Stat3. In freshly isolated Sz cells (n=3), Cucurbitacin I induces a concentration-dependent decrease in Stat3 expression whereas P-Stat3 is undetectable. Finally, incubation of freshly isolated Sz cells (n=4) with 30 μM Cucurbitacin I for 6 hours induces apoptosis in the large majority (73-91%) of tumor cells.
No major side effects are noted throughout the study. It is shown that average tumor volumes at the end of the study are as follows: control, 616 mm 3 (±130); CQ, 580 mm 3 (±107); Cucurbitacin I, 346mm 3 (±79); and combination, 220mm 3 (±62). The differences in tumor volume between the Cucurbitacin I and control, combination and control, and combination and Cucurbitacin I arms are significant. Furthermore, combination-treated tumors exhibit a significantly lower average tumor weight at study termination than the control. Moreover, there was no effect on the body weights of mice.